Introduction
The Notch genes encode a group of highly preserved transmembrane receptors that transmit signals affecting the development of organisms (1) (2) (3) (4) (5) (6) (7) (8) . The Notch receptor is composed of an extracellular ligand-binding domain (ECD) and an intracellular domain (ICD) for signal transduction. Notch signaling occurs as a result of cell-cell interaction between the Notch receptor on the target cell and the ligand on the adjacent cell, and involves the proteolytic cleavage and translocation of the ICD into the nucleus (9) . In humans, the Notch signaling pathway is involved in the development of the neural, muscular and lymphoid system (8, (10) (11) (12) (13) . Dysregulation of Notch expression has been found to contribute to several human diseases. The most striking example is T-cell lymphoid malignancy (14) (15) (16) .
Hematopoiesis involves a tightly regulated series of molecular events, whereupon lineage commitment or selfrenewal of stem cells may result from intrinsic and extrinsic stochastic processes. Studies have explored the potential role of the Notch signaling pathway in hematopoiesis; both Notch-1 and -2 were detected in murine marrow precursors (Lin -Sca-1 + c-kit + ), and the Jagged-1 ligand was observed in murine bone marrow stroma and stromal cell lines (17) . Cellcell interaction between hematopoietic and stromal cells via Notch receptor-ligand conjugation may influence cell fate and the self-renewing process of the hematopoietic system (18) . The classic view holds that Notch signaling keeps cells in an undifferentiated state. It is believed that Notch activity promotes hematopoietic progenitor self-renewal, and is involved in the control of cell fate, differentiation, proliferation and apoptosis (19) . However, this viewpoint changed after it was observed that Notch-1 signaling induced multilineage myeloid differentiation through direct increase of the mRNA level of the transcriptional factor PU.1 which mediates myeloid differentiation (20) . We therefore speculated that decreased Notch-1 expression may participate in the leukemogenesis of human myeloid malignancies.
Acute myeloid leukemia (AML) is a disease that originates from the dysregulation of myelopoiesis, and the role of the Notch signaling system in the leukemogenesis of AML is of great interest. At present, there are only limited studies Table I .
Isolation of CD34
+ cells as an experimental control. The CD34 + stem cells were used as a control for Notch-1 and related signal expression in this study. Five healthy donors underwent peripheral blood stem cell collection after signing an informed consent. Stem cell purging was performed using the cell isolation device CliniMACS ® on the day of stem cell harvest and for three consecutive days. During the stem cell purging procedure with CliniMACS, the cells were specifically labeled with superparamagnetic iron-dextran particles, which were covalently conjugated to the mouse anti-human CD34 antibody. After magnetic labeling, the CliniMACS system automatically passed the cells through a separation column, which was subjected to a strong permanent magnet. The magnetically labeled cells were retained in the column and separated from the unlabeled cells, which flowed through. The CliniMACS eluted the retained cells by removing the column from the magnetic field, washing the cells out, and collecting them. The CD34 + subpopulation of the purged stem cells was counted by flow cytometry.
AML cell lines and culture. Six AML cell lines (CTV, KG-1, RPMI-6410, MOLM13, THP1, GDM1) were cultivated under standard conditions. The cells were harvested for extraction of mRNA and protein for the subsequent analysis.
RNA extraction and real-time PCR.
Total RNA was extracted from various cell samples using RNAzol B reagents (Biotech Laboratories, Houston, TX) according to the manufacturer's protocol. To eliminate potentially contaminating DNA, the RNA samples were treated with DNase (1 unit per 10 μg total RNA), followed by organic solvent extraction and ethanol precipitation. Finally, the extracted RNA was dissolved in DEPC-treated sterile water, and the total RNA concentration was measured optically.
Quantitative real-time PCR for Notch-1 and PU.1 was performed in a PRISM 7700 Sequence Detection System (ABI) with the preset PCR program, and GAPDH was selected as an internal control. For Notch-1, 0.1 μg of cDNA and 80 μM of primers were used in the PCR reaction in 1X SYBR-Green Mixture (ABI) in a total volume of 50 μl. The target quantity was measured by identifying the threshold cycle number (C T ), i.e., when the fluorescence signal crosses a preset detection threshold. GAPDH was selected as an internal control for realtime PCR experiments. Transcript levels were normalized to those of GAPDH to account for variability in the amount of cDNA in each sample, and relative expression levels were Table I . Characteristics of the 54 AML patients. 
calculated using the 2 -ΔΔC T method (25) . The nucleotide sequences of primers and probes are listed in Table II .
Protein extraction, Western blotting and immunoprecipitation.
A total of 50 μg of cellular extracts of representative AML patient samples, CD34
+ stem cells and AML cell lines was used for Western blot analysis. After cell lysis and protein extraction, SDS-PAGE was performed, and then transferred to nitrocellulose membranes. The membranes were incubated with a polyclonal anti-Notch-1 antibody (sc-6014), anti-PU.1 antibody (sc-352), anti-MCSFR antibody (sc-692) and a polyclonal anti-ß-actin antibody (sc-7210) (all from Santa Cruz Biotechnology Inc., Santa Cruz, CA) as a control for protein loading. Signals were revealed using an Amersham ECL chemiluminescence kit (Amersham Pharmacia Biotech, Piscataway, NJ).
Immunoprecipitation was performed by incubating 1000 μg of whole cell extract from each AML cell line and samples with an anti-Notch-1 antibody with slow rotation for 4 h, and the immune complexes were incubated overnight with protein A-linked agarose beads (blocked with 10% BSA). The immunoprecipitate was washed three times with TNTG buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 0.1% Triton X-100, 10% glycerol), mixed with 1X Laemmli dye, boiled for 10 min and loaded to a 12% SDS gel. After protein transfer, the filter was blocked, probed with anti-PU.1 antibody and the secondary antibody sequentially. Immunocomplexes were detected with the ECL chemiluminescence kit (Amersham Biosciences, UK). PU.1-immnoprecipitation following Western blotting was also performed to confirm the bidirectional interaction. Data are representative of two or more experiments from independent cell cultures.
PCR-SSCP analysis of Notch-1 and PU.1. To identify any mutation or deletion existing in the Notch-1 and PU.1 gene, we tested the ANK domain and the PEST region of the Notch-1 receptor at the carboxy terminus of the cytoplasmic domain, and the PEST and DNA-binding domain (DBD) of PU.1 using single-strand conformation polymorphism (SSCP) followed by direct sequence analysis. The amplified fragment was analyzed for gene mutations using the SSCP method as previously described (26) . PCR product bands with a different mobility from that of the controls were excised and amplified, and the PCR products were sequenced using a dye-labeled terminator cycle sequencing kit (Perkin Elmer, Foster City, CA). The nucleotide sequences of specific primers used in this study are listed in Table II .
Statistical analysis. The statistical package of the Social Sciences software (version 13.0; SPSS, Inc., Chicago, IL) was used for statistical analysis. The Pearson correlation coefficient test was used to determine the degree of correlation between Notch-1 and PU.1 mRNA expression assays, with a value >0.6 deemed to be a significant correlation. The independent Student's t-test was used to compare relative Notch-1 or PU.1 mRNA expression between groups. The level of statistical significance was set at 0.05 for all tests. (Fig. 1C  and D) . This result indicates that down-regulation of Notch-1 mRNA and protein expression can be found in most AML cells, and may indicate that decreased Notch-1 expression may be a significant molecular event in the leukemogenesis of AML.
Results

Decreased
Down-regulation of Notch-1 expression decreased the expression of myeloid differentiation factors PU.1 and MCSFR in AML.
Since Notch-1 signaling induces myeloid differentiation through up-regulation of a transcriptional factor PU.1 which regulates myeloid differentiation during normal hematopoiesis (20) , we speculated that decreased Notch-1 expression in AML cells may impede the PU.1-mediated myeloid differentiation pathway. In order to evaluate the association between Notch-1 expression and the PU.1-mediated myeloid differentiation pathway in AML Table II . Nucleotide sequence of specific primers used in this study.
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- (Fig. 2C and D) . These results indicate that downregulation of Notch-1 expression reduces the PU.1-mediated multilineage myeloid differentiation signals in AML.
-----------------------------------------------
Partial disruption of the Notch-1/PU.1 complex in AML cells. We further investigated whether Notch-1 regulates myeloid differentiation not only through the transcriptional level but also by direct interaction with PU.1. To determine whether Notch-1 directly interacts with PU.1 in normal hematopoietic stem cells and whether the Notch-1/PU.1 complex is decreased in AML, immunoprecipitation of Notch-1 intracellular domain (ICD) and PU.1 was performed. As shown in Fig. 3 , the direct binding of Notch-1 and PU.1 was detected in CD34 + hematopoietic stem cells. In AML cell lines and representative patient samples, decreased Notch-1/ PU.1 complex was noted. This result indicates that Notch-1 regulates myeloid differentiation not only through the transcriptional level of PU.1, but also by direct interaction with PU.1. Partial disruption of the Notch-1/PU.1 complex was found in AML cells which may reduce the PU.1-mediated myeloid differentiation that promotes leukemogenesis.
No mutation was found in the major domains of Notch-1 and PU.1 in AML.
In order to test the mutational status of Notch-1 ICD and PU.1 in AML, PCR-SSCP analysis was performed in the Notch-1 intracellular ANK and PEST domain, and the PEST and DNA-binding domain (DBD) of the PU.1 of AML cell lines and representative patient samples. No notable genetic mutation was found in the Notch-1 ICD and PU.1 domains in the AML cell lines and patients (Fig. 4) . This result indicates that mutation of Notch-1 and PU.1 may be a rare event and may not correlate with the leukemogenesis of human AML.
Discussion
The prevailing view of Notch signaling in myeloid hematopoiesis supposes that Notch signals function principally to inhibit the differentiation of progenitor cells and allow the expansion of the progenitor pool (28) (29) (30) . However, this idea has been challenged by Schroeder et al. They reported that Notch-1 directly increases the PU.1 transcriptional level, which directs myeloid differentiation. Transiently activated Notch signaling can reduce the self-renewal of multipoint progenitors accompanied by increased and accelerated myeloid differentiation (20) . The contradiction between these two hypotheses may be explained by the difference between constitutive and inducible activation of Notch; constitutive activation could maintain the cells in the undifferentiated status, while inducible activation could result in myeloid differentiation. In our study, a quantitative gene assay was carried out to clarify the expression profile of the Notch signaling system in AML cell lines and primary AML cells.
The results revealed that Notch-1 gene expression was significantly decreased in the tested AML samples and cell lines compared with the normal hematopoietic stem cells (Fig. 1) . To test whether AML cells decreased Notch-1 protein (33) . According to the viewpoint mentioned above, down-regulation of Notch-1 expression in myeloid cells might lead to the blockage of differentiation and may participate in the development of AML. To the best of our knowledge, our study is the first to investigate the involvement of the Notch system in a large series of AML patients. During normal myeloid differentiation, a high level of transcriptional factor PU.1 activates promoters specific to myeloid cells, such as the M-CSF receptor (MCSFR) which controls differentiation. Since Notch-1 expression is downregulated in AML, we speculate that Notch-1-mediated myeloid differentiation signaling may be decreased in AML. In our study, significantly decreased PU.1 mRNA expression was found in AML patients ( Fig. 2A) and cell lines (data not shown). Western blot analysis also revealed that the PU.1 and MCSFR protein levels were reduced in AML patients and cell lines ( Fig. 2B and C) . Based on this result, we suggest that decreased Notch-1 expression in myeloid cells reduces the PU.1 expression level, which impedes myeloid differentiation and induces AML.
Notch-1 regulates myeloid differentiation through increasing PU.1 mRNA expression levels; a high concentration of PU.1 is essential for myeloid differentiation. However, we speculated about a possible mechanism involving Notch-1/ PU.1 interaction other than transcriptional regulation. Coimmunoprecipitation of Notch-1 ICD and PU.1 in normal hematopoietic cells revealed that direct binding could occur between Notch-1 and PU.1. Decreased co-immunoprecipitation of Notch-1 ICD/PU.1 was found in AML cells (Fig. 3) . We believe that Notch-1 regulates PU.1, not only at the transcriptional level, but also by direct interaction. After ligand binding of the Notch receptor, the ICD cleaves and binds to PU.1, which regulates its function. Partial disruption of the Notch-1 ICD/PU.1 complex might be involved in the leukemogenesis of AML.
The transcriptional factor PU.1 normally suppresses the development of myeloid leukemia; gene deletion and mutation of PU.1 impairs its DNA-binding ability, which induces leukemia in mice. Mutation of Notch-1 ICD also blocks the signal transduction. We therefore speculated that the mutation of Notch-1 ICD or PU.1 impedes the myeloid differentiation signals that cause leukemia. PCR-SSCP analysis was performed to detect possible mutations in the major regions of Notch-1 ICD (ANK, PEST) and in PU.1. No mutation was found in either the AML cell lines or in the patients. Thus, abnormal Notch signaling in AML might have been due to the down-regulation of Notch-1 expression, which reduces myeloid differentiation signaling, since there were no mutations that prohibited Notch signal transduction.
In conclusion, our novel study delineated the role of Notch-1 and myeloid differentiation factors PU.1 and MCSFR in AML patients. Down-regulation of Notch-1 expression reduced PU.1-mediated myeloid differentiation signaling in the AML patients and cell lines. Dual regulation of PU.1 by Notch-1 at the transcriptional level and by protein interaction was demonstrated in normal hematopoietic stem cells. Partial disruption of the Notch-1 ICD/PU.1 interaction might impair PU.1 function, which induces leukemia. No mutation of Notch-1 ICD and PU.1 was demonstrated in AML. These results suggest that down-regulation of Notch-mediated myeloid differentiation signaling might play an essential role in the development of AML.
